Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 1 von 3
Annals of allergy, asthma, & immunology, 2013-03, Vol.110 (3), p.194-197.e4
2013
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey
Ist Teil von
  • Annals of allergy, asthma, & immunology, 2013-03, Vol.110 (3), p.194-197.e4
Ort / Verlag
United States: Elsevier Inc
Erscheinungsjahr
2013
Quelle
MEDLINE
Beschreibungen/Notizen
  • Abstract Background Limited information regarding current trends of sublingual immunotherapy (SLIT) use, perception, and prescribing patterns among allergists in the United States is available. Objective To obtain information about current allergist perception and practice of SLIT compared with 2007. Methods On behalf of the American College of Allergy, Asthma and Immunology (ACAAI) Immunotherapy and Diagnostics Committee, an electronic survey was sent to all practicing allergists of the ACAAI in August 2011. Results Fifty-nine of 519 US respondents (11.4%) reported experience using SLIT compared with 45 of 766 (5.9%) in 2007 ( P < .001). Lack of Food and Drug Administration (FDA) approval was the primary barrier in using SLIT in the United States among 469 of 520 respondents (90.2%), which was increased from 471 of 763 (61.7%) in 2007 ( P < .001). Among US respondents, 344 of 516 (66.7%) believed that SLIT was safer than subcutaneous immunotherapy (SCIT) compared with 554 of 755 (73.4%) in 2007 ( P < .01). In total, 22 of 51 SLIT users (43.1%) reported SLIT efficacy equal to or even greater than SCIT, which was similar to 21 of 38 (55.3%) reported in 2007 ( P < .36). Conclusion Rates of SLIT use reported by US respondents have nearly doubled in the last 4 years, with 11.4% of US respondents reporting SLIT use. Because the greatest barrier to SLIT use in the United States is the lack of FDA approval, it is anticipated that once an FDA-approved product is available, there will be widespread use of SLIT in the United States. Practice guidelines, which include effective dosages and schedules, will be critical to the broad implementation of SLIT in the United States.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX